Sun Pharmaceutical Industries Limited

Address: Sun House Plot No 201 B/1, Western Express Highway, Goregaon East

Sponsor Overview

assignment

Specializations

Dermatology and Inflammatory Skin Disease

Psoriasis, atopic dermatitis, and related inflammatory skin disorders are central areas of interest, including plaque psoriasis, genital psoriasis, and pediatric chronic plaque psoriasis.

Plaque psoriasis
Atopic dermatitis
Genital psoriasis
Pediatric psoriasis
Moderate to severe plaque psoriasis

Research also extends to moderate to severe genital psoriasis and chronic plaque psoriasis in children and adolescents.

Rheumatology and Autoimmune Disease

The sponsor funds studies in psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis, Crohn’s disease, and ulcerative colitis, reflecting a strong focus on immune-mediated conditions.

Psoriatic arthritis
Rheumatoid arthritis
Axial spondyloarthritis
Crohn’s disease
Ulcerative colitis

Additional interest includes ulcerative colitis with overlapping inflammatory bowel disease and spondyloarthritic manifestations.

Oncology and Hematologic Malignancies

Clinical research includes multiple cancer and hematology indications, particularly chronic myeloid leukemia, acute lymphoblastic leukemia, myelofibrosis, polycythemia vera, and prostate cancer.

Chronic myeloid leukemia
Acute lymphoblastic leukemia
Myelofibrosis
Polycythemia vera
Prostate cancer

Work also covers melanoma, non-small cell lung cancer, anaplastic thyroid cancer, and other BRAF mutation-positive solid tumors.

Metabolic, Neurologic, and Psychiatric Disorders

The sponsor’s portfolio includes type 2 diabetes mellitus, epilepsy, epileptic seizures, attention deficit hyperactivity disorder, bipolar disorder, and major depressive disorder.

Type 2 diabetes mellitus
Epilepsy
Attention deficit hyperactivity disorder
Bipolar disorder
Major depressive disorder

Other areas include seasonal affective disorder, alcohol dependence, and binge eating disorder.

Transplantation, Infectious Disease, and Urologic Conditions

Further research spans cytomegalovirus infection in transplant recipients, graft-versus-host disease, cystic fibrosis, and infectious diseases more broadly, alongside benign prostatic hyperplasia.

Cytomegalovirus infection
Graft-versus-host disease
Cystic fibrosis
Infectious diseases
Benign prostatic hyperplasia

These studies also include post-transplant viral complications and urologic disease management.

Sponsored Trials

Trial Name	Country	Status
A Randomized, Open-Label, Two-Period, Crossover Bioequivalence Study of Deucravacitinib 6 mg Tablets in Healthy Adult Subjects Under Fasting Conditions	Romania	Not Recruiting
A Randomized, Open-Label, Two-Period, Two-Sequence, Crossover Bioequivalence Study of Deucravacitinib 6 mg Tablets in Healthy Adult Subjects Under Fed Conditions	Romania	Not Recruiting
A Randomized, Open-Label, Two-Period, Two-Sequence, Crossover Bioequivalence Study of Maribavir 200 mg in Healthy Adult Subjects Under Fasting Conditions	Romania	Not Recruiting
A Randomized, Open-Label, Two-Period, Two-Sequence, Crossover Bioequivalence Study of Ponatinib 15 mg in Healthy Adult Subjects under Fasting Conditions	Romania	Not Recruiting
A Randomized, Two-Period, Two-Sequence, Crossover Bioequivalence Study of Bupropion Hydrochloride Sustained-Release Tablets in Healthy Adult Volunteers under Fed Conditions	Romania	Not Recruiting
An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis.	Czechia Estonia Germany Italy Poland Slovakia Spain	Not Recruiting
Bioequivalence of a Generic Fexofenadine 180 mg/Pseudoephedrine 240 mg Extended‑Release Tablet Versus Allegra‑D 24 HR in Healthy Adults for Seasonal Allergic Rhinitis	Romania	Not Yet Recruiting
Bioequivalence of Generic Fexofenadine HCl/Pseudoephedrine HCl Extended‑Release 180 mg/240 mg Tablet versus Reference Formulation in Healthy Adults under Fed Conditions (Seasonal Allergic Rhinitis)	Romania	Not Yet Recruiting
Bioequivalence of Imatinib Mesylate Tablets 400 mg vs Reference Formulation in Healthy Adults Under Fed Conditions	Romania	Not Yet Recruiting
Bioequivalence of Trametinib 2 mg Tablets vs Reference in Healthy Adults Under Fasting Conditions	Romania	Not Yet Recruiting